Results of intravenous thrombolysis within 4.5 to6hours and updatedresults within 3 to 4.5 hours of onset ofacute ischemic strokerecorded in the safe implementation of treatment in stroke international stroke thrombolysis register (SITS-ISTR) an observational study

JAMA Neurology

Volumn 70, Issue 7, 2013, Pages 837-844

  Ahmed, Niaz ^a   Kellert, Lars ^b   Lees, Kennedy R ^c   Mikulik, Robert ^d   Tatlisumak, Turgut ^e   Toni, Danilo ^f  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EMERGENCY CARE; EUROPE; FEMALE; FIBRINOLYTIC THERAPY; FUNCTIONAL ASSESSMENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RANKIN SCALE; TIME;

EID: 84880255298     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.406     Document Type: Article

References (16)

1. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr; American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009;40(8):2945-2948.
2. European Stroke Organisation (ESO) Executive Committee; ESOWriting Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457-507.
3. HackeW, Kaste M, Bluhmki E, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4. 5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329.
4. Wahlgren N, Ahmed N, Dávalos A, et al; SITS investigators. Thrombolysis with alteplase 3-4. 5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372(9646): 1303-1309.
5. HackeW, Donnan G, Fieschi C, et al; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768-774.
6. Lees KR, Bluhmki E, von Kummer R, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695-1703.
7. Safe Implementation of Treatment in Stroke (SITS). SITS website. https://sitsinternational.org. Accessed May 29, 2012.
8. Wahlgren N, Ahmed N, Dávalos A, et al; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558): 275-282.
9. Ahmed N, Wahlgren N, Grond M, et al; SITS investigators. Implementation and outcome of thrombolysis with alteplase 3-4. 5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol. 2010;9(9):866-874.
10. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581-1587.
11. Larrue V, von Kummer R, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001;32(2): 438-441.
12. Mikulík R, Kadlecová P, Czlonkowska A, et al; Safe Implementation of Treatments in Stroke-East Registry (SITS-EAST) Investigators. Factors influencing in-hospital delay in treatment with intravenous thrombolysis. Stroke. 2012;43(6): 1578-1583.
13. Saver JL. Time is brain-quantified. Stroke. 2006;37(1):263-266.
14. The IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial [published correction appears in Lancet. 2012;380(9843):730]. Lancet. 2012;379(9834): 2352-2363.
15. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604-607.
16. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379(9834): 2364-2372.